Skip to main content

Meningococcemia and Purpura Fulminans

  • Chapter
Deadly Dermatologic Diseases
  • 892 Accesses

Abstract

Meningococcemia is an invasive bacterial infection by the gram-negative diplococcus, Neisseria meningitidis, which is often rapidly fatal if not detected and treated early. Neisseria meningitidis infections occur both endemically and epidemically. Sporadic disease occurs more commonly during winter and early spring months, and affects predominantly children. The highest rate of infection is in infants six months to one year, with a steady decline in infection rate with age. This is likely explained by passive maternal immunity providing protection in the first six months, and gradual onset of acquired immunity with age. Approximately two-thirds of invasive meningococcal disease occurs in children (1). The human bacterial reservoir is the upper respiratory tract. In the general population, the carrier state is quite common, but in only rare cases do carriers develop invasive disease. There are many different serotypes of Neisseria meningitidis, but types A, B, C, W-135, and Y account for nearly all invasive disease. Worldwide, type A is responsible for most large epidemics, but in the United States, serotypes B and C account for approximately 90% of invasive infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: Results of a 5-year population-based study. Ann Intern Med 1995;123:937–940.

    PubMed  CAS  Google Scholar 

  2. Salzman MB, Rubin LG. Meningococcemia. Infect Dis Clin N Am 1996;10:709–725.

    Article  CAS  Google Scholar 

  3. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child 2003;88:601–607.

    Article  PubMed  CAS  Google Scholar 

  4. Ellison RT, Kohler PF, Curd JG, Judson FN, Reller LB. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N Engl J Med 1983;308:913–916.

    Article  PubMed  Google Scholar 

  5. Adams EM, Hustead S, Rubin P, Wagner R, Gewurz A, Graziano FM. Absence of the seventh component of complement in a patient with chronic meningococcemia presenting as vasculitis. Ann Intern Med 1983;99:35–38.

    PubMed  CAS  Google Scholar 

  6. Denson P, Weiler JM, Griffiss JM, Hoffmann LG. Familial properdin deficiency and fatal meningococcemia. N Engl J Med 1987;316:922–926.

    Article  Google Scholar 

  7. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999;353:1049–1053.

    Article  PubMed  CAS  Google Scholar 

  8. Ellison RT, Mason SR, Kohler PF, Curd JG, Reller B. Meningococcemia and acquired complement deficiency: Association in patients with hepatic failure. Arch Intern Med 1986;146:1539–1540.

    Article  PubMed  Google Scholar 

  9. Bass J, Nuss R, Mehta KA, Morganelli P, Bennett L. Recurrent meningococcemia associated with IgG2-subclass deficiency. N Engl J Med 1983;309:430.

    PubMed  CAS  Google Scholar 

  10. Castagliuolo PP, Nisini R, Quinti I, Fattorossi A, D’Amelio R. Immunoglobulin deficiencies and meningococcal disease. Ann Allergy 1986;57:68–70.

    PubMed  CAS  Google Scholar 

  11. Ploysangam T, Sheth AP. Chronic meningococcemia in childhood: Case report and review of the literature. Pediatr Dermatol 1996;13:483–487.

    PubMed  CAS  Google Scholar 

  12. Assier H, Chosidow O, Rekacewicz I, et al. Chronic meningococcemia in acquired immunodeficiency infection. J Am Acad Dermatol 1993;29:793–794.

    Article  PubMed  CAS  Google Scholar 

  13. McClean S, Caffey J. Endemic purpuric meningococcus bacteremia in early life: The diagnostic value of smears from the purpuric lesions. Am J Dis Child 1931;42:1053–1074.

    Google Scholar 

  14. Young EJ, Cardella TA. Meningococcemia diagnosed by peripheral blood smear. JAMA 1988;260:992.

    Article  PubMed  CAS  Google Scholar 

  15. Darmstadt GL. Acute infectious purpura fulminans: Pathogenesis and medical management. Pediatr Dermatol 1998;15:169–183.

    Article  PubMed  CAS  Google Scholar 

  16. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995;127:355–363.

    Article  PubMed  CAS  Google Scholar 

  17. Kullberg BJ, Westendorf RGJ, van’t Wout JW, Meinders AE. Purpura fulminans and symmetrical gangrene caused by Capnocytophaga canimorsus (formerly DF-2) septicemia—a complication of dog bite. Medicine 1991;70:287–292.

    Article  PubMed  CAS  Google Scholar 

  18. Jackson RT, Luplow RE. Adult purpura fulminans and digital necrosis associated with sepsis and the Factor V mutation. JAMA 1998;280:1829.

    Article  PubMed  CAS  Google Scholar 

  19. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408–416.

    Article  PubMed  CAS  Google Scholar 

  20. Warner PM, Kagan RJ, Yakuboff KP, et al. Current management of purpura fulminans: A multicenter study. J Burn Care Rehabil 2003;24:119–126.

    Article  PubMed  CAS  Google Scholar 

  21. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPi21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. rBPi21 Meningococcal Sepsis Study Group. Lancet 2000;356:961–967.

    Article  PubMed  CAS  Google Scholar 

  22. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.

    Article  PubMed  CAS  Google Scholar 

  23. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection. J Pediatr 1966;68:457–467.

    Article  PubMed  CAS  Google Scholar 

  24. Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicemia. Lancet 1987;350:38.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

(2007). Meningococcemia and Purpura Fulminans. In: Deadly Dermatologic Diseases. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68858-9_29

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68858-9_29

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-25442-5

  • Online ISBN: 978-0-387-68858-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics